GET DAILY SIGNALSLENSAR (LNSR) Q3 2026 Earnings Preview: Flat Revenue Expected After +18% Growth
Key Takeaways
- LENSAR, Inc. is scheduled to report its third quarter 2026 results before the market opens on Tuesday, November 10, 2026, with a conference call at 8:30 a.m. ET.
- Consensus estimates call for a net loss of about $0.095 per share on revenue of roughly $14.30 million.
- That revenue estimate is nearly flat compared with the $14.32 million LNSR reported in the third quarter of 2025.
- In the prior quarter (Q2 2026), LENSAR posted adjusted EPS of $0.10 on revenue of $16.5 million, up 18% year over year.
- Recurring revenue reached $13.7 million, or about 83% of total sales, in the second quarter of 2026.
- Management has signaled that the third quarter typically sees seasonal procedure softness along with higher operating expenses.
- For more context, readers can explore the company's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Investors interested in automated market insights can also explore Trending AI Robots.
Why LENSAR's Results Matter Right Now
LENSAR is a commercial-stage medical technology company focused on advanced robotic laser systems for cataract surgery, anchored by its ALLY Robotic Cataract Laser System. Its quarterly results offer investors a direct read on both system placements and the recurring revenue generated from procedures performed on its installed base. The report arrives as LENSAR works through a strategic reset following the termination of its planned merger with Alcon, refocusing efforts on expanding the ALLY installed base and rebuilding international distributor relationships. Given that recurring revenue represented roughly 83% of total sales last quarter, this report will show whether that high-margin revenue stream can offset an expected seasonal dip in procedure volumes, making it a key indicator of the company's path toward sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations for the Quarter
For the third quarter of 2026, Wall Street consensus points to a net loss of approximately $0.095 per share on revenue near $14.30 million, according to analyst estimates tracked by MarketBeat. That top-line expectation is essentially flat against the $14.32 million LENSAR generated in the same period a year ago, reflecting management's caution about seasonal procedure weakness during the summer months.
The setup contrasts sharply with the prior quarter, when LENSAR delivered adjusted EPS of $0.10, beating expectations by a wide margin, alongside 18% year-over-year revenue growth to $16.5 million. Recurring revenue climbed 20% to $13.7 million, and adjusted EBITDA reached a record $3.6 million. Investors will be watching whether the recurring revenue base can hold up against the expected seasonal slowdown and rising operating expenses tied to commercial and international expansion.
Market Sentiment Heading Into the Report
Sentiment heading into the November 10 report reflects a mix of optimism about LENSAR's improving recurring revenue profile and caution over the seasonal and cost dynamics that management has flagged. The stock has benefited from a strong second quarter, but the consensus expectation of a modest net loss for Q3 2026 suggests analysts are bracing for a pullback in profitability. Key risk factors include weaker procedure volumes, rising spending on commercial and international initiatives, and any lingering uncertainty following the Alcon merger termination. Investors will likely focus less on the headline loss and more on recurring revenue trends, gross margin, and any commentary on system placements and utilization. From what I see, this balance between recurring strength and seasonal pressure is what makes the upcoming print particularly telling.
Forward Outlook and Key Factors to Monitor
Looking beyond the third quarter, investors should monitor several factors tied to LENSAR's ability to sustain its recurring revenue momentum. The durability of the ALLY system's installed base expansion will be central, as each additional placed system adds to the procedure-driven revenue stream that now accounts for the large majority of total sales. Commentary on gross margin and adjusted EBITDA will also matter, particularly given that management has previously described its roughly 52% adjusted gross margin as sustainable as the recurring model scales.
On the cost side, rising operating expenses from commercial and international investments could pressure near-term profitability even if revenue holds steady. Investors should watch for any update on guidance or full-year expectations, since the company has not historically issued formal guidance and instead relies on qualitative commentary about procedure trends and seasonality.
Finally, industry dynamics in premium cataract surgery and competitive positioning against emerging femtosecond laser-assisted cataract surgery (FLACS) systems remain important long-term variables. Signs of stabilizing system sales, improving international distribution, or accelerating procedure utilization would be notable signals for the quarters ahead. I'm watching this closely as the company rebuilds its momentum post-merger termination.
Exploring AI-Powered Research Tools
In my analysis of names like LENSAR, I often turn to Tickeron’s AI Screener to quickly filter for comparable medical technology stocks and surface technical or fundamental signals that might otherwise take hours to identify manually. It helps me cross-check industry trends and spot potential peers with similar recurring-revenue profiles. This kind of tool has become a regular part of how I prepare for earnings seasons, offering a structured way to validate ideas before digging deeper into individual reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LNSR in -4.62% downward trend, sliding for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where LNSR declined for three days, in 232 of 278 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LNSR as a result. In 76 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Aroon Indicator for LNSR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LNSR's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for LNSR just turned positive on October 23, 2026. Looking at past instances where LNSR's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +6.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNSR advanced for three days, in 199 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
LNSR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.534) is normal, around the industry mean (4.115). P/E Ratio (4.545) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.120) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. LNSR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LNSR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement